Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-10-09
2007-10-09
Wax, Robert A (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
10451370
ABSTRACT:
Methods and compositions employing plaque associated molecules effective in inducing mucosal tolerance and inhibiting inflammatory processes contributing to atheromatous vascular disease and sequalae are provided.
REFERENCES:
patent: 4874769 (1989-10-01), Youssefyeh et al.
patent: 4874795 (1989-10-01), Yesair
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5409710 (1995-04-01), Leonard
patent: 6225070 (2001-05-01), Witztum et al.
patent: 6497880 (2002-12-01), Wisniewski
patent: 6541011 (2003-04-01), Punnonen et al.
patent: 2003/0114367 (2003-06-01), Schoenfeld et al.
patent: 2005/0148499 (2005-07-01), Harats et al.
patent: 2005/0197283 (2005-09-01), Harats et al.
patent: WO 98/16248 (1998-04-01), None
patent: WO 00/20019 (2000-04-01), None
patent: WO 01/68119 (2001-09-01), None
patent: WO 01/68124 (2001-09-01), None
Lindquinst et al., Ann. Rev. Biochem, 1986, vol. 55, pp. 1151-1191.
Schlesinger, et al., J. Cell Biol., 1986, vol. 103, pp. 321-325.
Palinski et al., Proc. Natl. Acad. Sci., 1995, vol. 92, pp. 821-825.
Ameli et al., Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, vol. 16, pp. 1074-1079.
Kobayashi et al., Journal of Lipid Research, 2001, vol. 42, pp. 697-709.
Xu et al., Arteriosclerosis and Thrombosis, 1992, vol. 12, pp. 789-799.
Xiao et al., Clincial Immunology and Immunopathology, 1997, vol. 85, pp. 119-128.
George et al. “Hyperimmunization of Apo-E-Deficient Mice With Homologous Malondialdehyde Low-Density Lipoprotein Suppresses Early Atherogenesis”, Atherosclerosis, 138: 147-152, 1998.
Bonnin et al. “Mucosol Modulation of Immune Responses to Heat Shock Proteins in Autoimmune Arthritis”, Biotherapy, 10(3); 213-221, 1998. Abstract.
George et al. “Induction of Early Atherosclerosis in LDL-Receptor Deficient Mice Immunized With β2-Glycoprotein I”, Circulation, 98: 1108-1115, 1998.
George et al. “Altherosclerosis-Related Markers in Systematic Lupus Erythematosus Patients: The Role of Humoral Immunity in Enhanced Atherogenesis”, Lupus, 8: 220-226, 1999.
Hansson et al. “Autoimmunity In Atherosclerosis”, Atherosclerosis, 134 (1-2): 289, 1997. Abstract. & 11th International Symposium on Atherosclerosis, p. 289, 1997.
Sima et al. “Modified Lipoproteins Generate Autoantibodies and Accumulate in the Arterial Lesions of Athero-Diabetic Patients and Hamsters”, Atherosclerosis, 134 (1-2): 227, 1997. Abstract. & 11th International Symposium on Atherosclerosis, p. 227, 1997. Abstract.
Resch et al. “Competition-Studies With Antioxidized LDL Autoantibodies”, Atheresclerosis, 132 (1-2): 227, 1997. Abstract.
McKown et al. “Lack of Efficacy of Oral Bovine Type II Collagen Added to Existing Therapy in Rheumatoid Arthritis”, Journal of Arthritis & Rheumatism, 42(6): 1204-1208, 1999.
Spack et al. “Antigen-Specific Therapies for the Treatment of Multiple Sclerosis: A Clinical Trial Update”, Expert Opinion on Investigational Drugs, 6(11): 1715-1727, 1997.
Lymaye et al. “Evaluation of Antibodies to β2-Glycoprotein 1 in the Causation of Coronary Atherosclerosis as Part of the Antiphospholipid Syndrome”, AU/NZ Journal of Medicine, 29: 789-793, 1999.
Blanas et al. “Induction Autoimmune Diabetes by Oral Administration of Autoantigen” Science, 274(5293): 1707. Abstract.
Pech et al. “LDL Modifiées et Athérosclérose. Nature des Modifications. Propriétés Physicochimiques et Biologiques”. Ann. Biol. Clin., 50: 213-227, 1992.
Hoff et al. “Structure of Cholesterol-Containing Particles Accumulating in Atherosclerotic Lesions and Mechanisms of Their Derivation”, Current Opinion in Lipidologya, 6: 317-325, 1995.
Shen et al. “From Interaction of Lipidic Vehicles With Intestinal Epithelial Cell Membranes to the Formation and Secretion of Chylomicrons”, Advanced Drug Delivery Reviews, 50: S103-S125, 2001.
Maurer et al. “Developments in Liposomal Drug Delivery Systems”, Expert Opinion Biol. Ther., 1(6): 1-24, 2001.
Emeson et al. “Accelerated Atherosclerosis in Hyperlipidemic C57BL/6 Mice Treated With Cyclosporin A”, American Journal of Pathology, 142(6): 1006-, 1993.
Meir et al. “Inflammation in Atherosclerosis—Causal or Casual ? The Need for Randomized Trials of Anti-Inflammatory Agents”, Department of Medicine B, Hadassah University Hospital.
Williams “Rodent Models of Arthritis: Relevance for Human Disease”, Clin. Exp. Immunol., 114: 330-332, 1998.
Fujinami et al. “Myelin Basic Protein Serum Factor—An Endogenous Neuroantigen Influencing Development of Experimental Allergic Ecephalomyelitis Allergic Encephalomyelitis in Lewis Rats”, Journal Exp. Med. , 148: 1716-1721, 1978.
Ogra et al. “Vaccination Strategies for Mucosol Immune Responses”, Clinical Microbiology Review, p. 430-445, 2001.
Lehner et al. “The Effect of Route of Immunzation on Mucosol Immunity and Protection”, The Journal of Infectious Diseases, 179(Suppl 3):S489-S492, 1999.
Chen “Recent Advances in Mucosol Vaccine Development”, Journal of Controlled Release, 67: 117-128, 2000.
Freigang et al. “Immunization of LDL Receptor-Deficient Mice With Homologous Malondialdehyde-Modified and Native LDL Reduces Progression of Atherosclerosis by Mechanisms Other Than Induction of High Titers of Antibodies to Oxidative Neopitopes”, Arterioscler. Thromb. Vasc. Biol., 18: 1972-1982, 1998.
Zhou et al. “LDL Immunization Induces T-Cell-Dependent Antibody Formation and Protection Against Atherosclerosis”, Arteriscler. Thromb. Vasc. Biol., 21: 108-114, 2001.
Mol et al. “The Role of Modification of Lipoproteins and of the Immune System in Early Atherogenesis”, Netherland Journal of Medicine, 43(1-2): 83-90, 1993.
Resch et al. “Competition-Studies With Antioxidized LDL Autoantibodies”, 11th International Symposium on Atherosclerosis, Paris, 3.P.138, p. 227, 1997. Abstract.
Shen et al. “A Delayed Transient Elevation of Protein Kinase C Activity Is Associated With Oxidized Liporotein(a)-Induced Production of Plasminogen Activator Inhibitor-1 in Vascular Endothelial Cells”, 11th International Symposium on Atherosclerosis, Paris, 3.P.137, p. 227, 1997, Abstract.
Tertov et al. “Atherogenicity of Low Density Lipoprotein Does Not Correlate With The Degree of Its Oxidation”, 11th International Symposium on Atherosclerosis, Paris, 3.P.139, p. 227, 1997. Abstract.
Matsuura et al “Are Oxidized LDL/β2-Glycoprotein I Complexes Pathogenic Antigens in Autoimmune-Mediated Atherosclerosis?”, Clinical Development Immunology, 11(2): 103-11, 2004. Abstract.
Cockerill et al. “Detection and Characterization of B Cell Epitopes on β2-Glycoprotein I”, Clinical Immunology, 112(2): 129-135, 2004. Abstract.
George et al. “Adoptive Transfer of β2-Glycoprotein I-Reactive Lymphocytes Enhances Early Atherosclerosis in LDL Receptor-Deficient Mice”, Circulation, 102: 1822-1827, 2000.
George et al. “Suppression of Early Atherosclerosis in LDL-Receptor Deficient Mice by Oral Tolerance With β2-Glycoprotein I”, Cardiovascular Research, 62: 603-609, 2004.
Vaarala et al. “Antibodies to Prothrombin Imply A Risk of Myocardial Infarction in Middle-Aged Men”, Thrombosis and Haemostasis, 75(3): 456-459, 1996.
George et al. “The Prediction of Coronary Atheresclerosis Employing Artifical Neural Networks”, Clinical Cardiology, 23: 453-456, 2000.
Sherer et al. “Coronary Artery Disease But Not Coronary Calcification Is Associated With Elevated Levels of Cardiolipin, β2-Glycoprotein-I, and Oxidized LDL Antibodies”, Cardiology, 95: 20-24, 2001.
Sherer et al. “Autoantibodies to Cardiolipin and β-2-Glycoprotein-I in Coronary Artery Disease Patients With and Without Hypertension”, Cardiology, 97: 2-5, 2002.
George Jacob
Harats Dror
Vascular Biogenics Ltd.
Wax Robert A
LandOfFree
Methods employing and compositions containing plaque... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods employing and compositions containing plaque..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods employing and compositions containing plaque... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3851178